TL;DR
This scoping review synthesizes evidence on the link between high uric acid levels (hyperuricemia, HUA) and erectile dysfunction (ED), finding a strong association but questioning HUA's independent role. The proposed mechanism involves a "oxidative stress-inflammation-metabolism" triad, suggesting potential for uric acid-lowering therapies, though more research is needed.
What Problem Does This Paper Address?
Erectile dysfunction (ED) is a common condition with multifactorial causes, often linked to cardiovascular diseases, diabetes, and metabolic syndrome. Hyperuricemia (HUA), characterized by elevated uric acid levels, is also associated with these conditions. While studies suggest a connection between HUA and ED, there's ongoing debate about whether HUA is a direct, independent risk factor or merely a marker of underlying health issues. This ambiguity has significant clinical implications: if HUA directly contributes to ED, uric acid-lowering treatments could become a new therapeutic strategy. Conversely, if it's just a symptom, management should focus on broader cardiovascular risk factors. This review aims to clarify this relationship by systematically examining existing research.
Methods
The authors conducted a scoping review, a method well-suited for exploring emerging research areas with diverse study designs and outcomes. They followed the PRISMA-ScR guidelines and searched major databases (PubMed, Web of Science, Scopus, Google Scholar) for clinical studies investigating the HUA-ED link. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies and the Appraisal tool for Cross-Sectional Studies (AXIS) for cross-sectional studies. Due to heterogeneity in study designs and populations, a narrative synthesis approach was used instead of a quantitative meta-analysis.
Datasets
Not applicable. This paper is a review of existing literature and does not introduce new datasets.
Key Insights and Ideas
- Strong Association, Unclear Independence: The vast majority of studies (93.8%) found a positive correlation between HUA and ED. However, only a smaller fraction (31.3%) confirmed this association persisted after accounting for confounding factors, and even fewer identified HUA as an independent risk factor. This suggests that while HUA is linked to ED, other underlying conditions might be driving the relationship.
- The "Oxidative Stress-Inflammation-Metabolism" Triad: The review proposes a unifying mechanistic framework where HUA contributes to ED through a complex interplay of oxidative stress, inflammation, and metabolic dysregulation. This triad offers a plausible explanation for how elevated uric acid can damage vascular function and contribute to ED.
- Heterogeneity is a Major Hurdle: A significant challenge identified is the lack of standardized definitions for hyperuricemia across studies. Most studies used non-standardized criteria, making direct comparisons and robust conclusions difficult. This methodological inconsistency is a key limitation.
- Gout as a Proxy: High-quality cohort studies, particularly those involving gout patients (a condition directly caused by uric acid crystal deposition), provided stronger evidence for an increased risk of ED. This suggests that conditions with clearly elevated uric acid levels are more reliably linked to ED.
Key Results
- Out of 16 included studies (totaling 295,705 participants), 15 showed a positive correlation between HUA and ED.
- Only 5 studies demonstrated that the association persisted after adjusting for confounding factors.
- Two studies identified HUA as an independent risk factor for ED.
- An exploratory pooled analysis of three high-quality cohort studies indicated that patients with gout had a 16% increased risk of developing ED (HR = 1.16, 95% CI 1.104–1.219). This finding should be interpreted cautiously due to the limited number of studies.
- Cross-sectional studies, which cannot establish causality, formed the majority (75%) of the included research.
Limitations and Future Work
The authors acknowledge several limitations:
- Heterogeneity: Inconsistent definitions of hyperuricemia and varied study designs (predominantly cross-sectional) limit the ability to draw definitive causal conclusions and perform quantitative meta-analyses.
- Geographic Bias: A significant portion of studies focused on Asian populations, potentially limiting the global applicability of the findings.
- Publication Bias: The possibility of publication bias cannot be excluded.
Future research directions include:
- Large-scale, Multicenter Cohort Studies: Prioritizing studies with standardized definitions for HUA and ED.
- Intervention Studies: Evaluating the direct impact of uric acid-lowering therapies on erectile function to establish causality and clinical relevance.
- Mechanistic Research: Exploring dose-response relationships and potential non-linear effects of uric acid on erectile function.
- Genetic and Environmental Factors: Investigating how these factors might influence the HUA-ED relationship and explain population differences.
In clinical practice, the review suggests focusing on comprehensive cardiovascular risk management rather than solely on uric acid levels for ED patients, while acknowledging the potential role of uric acid-lowering therapies pending further validation.
Summary updated